In the third quarter, biotech investors dramatically dialed down their risk tolerance. As a result, share values of small and midsized drug developers dipped almost 6 percent in September and, as a result, the BioWorld Drug Developers index returned a flat third quarter. In contrast, blue chip biopharmas enjoyed an excellent quarter, with the BioWorld Biopharmaceutical index outperforming the general markets.